| Title | Author(s) | Year | View Count |
 | Antiviral activity and safety of LB80380 in hepatitis B e antigen-positive chronic hepatitis B patients with lamivudine-resistant disease | Yuen, MF; Han, KH; Um, SH; Yoon, SK; Kim, HR; Kim, J; Kim, CR; Lai, CL | 2010 | 57 |
| A randomized placebo-controlled, dose-finding study of oral LB80380 in HBeAg-positive patients with chronic hepatitis B | Yuen, MF; Kim, J; Kim, CR; Ngai, V; Yuen, JCH; Min, C; Kang, HM; Shin, BS; Yoo, SD; Lai, CL | 2006 | 202 |
 | Phase II multi-centre, dose-escalating study of LB80380 (ANA380) in hepatitis B patients with lamivudine-resistant YMDD mutant HBV | Lai, CL; Han, KH; Yoon, SK; Um, SH; Yuen, MF; Kim, HS; Kim, HR; Chung, HC; Kim, CR; Hsyu, P; Averett, D; Worland, S; Kim, J | 2006 | 197 |
| Phase I/II double-blind, randomized, placebo-controlled study of the novel anti-HBV agent LB80380/ANA380 in patients with chronic HBV infection. | Yuen, RMF; Kim, J; Averett, D; Wong, DKH; Kim, CR; Kerr, B; Ngai, WS; Yuen, JCH; Lai, CL | 2004 | 197 |
|
